Are you Dr. Chand?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 28 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2013 Jefferson St Sw
Second Floor
Roanoke, VA 24014Phone(540) 982-0237Fax(540) 982-0103- Is this information wrong?
Summary
- Dr. Vikram Chand, MD is an oncologist in Roanoke, Virginia. He is currently licensed to practice medicine in Virginia, Connecticut, and Iowa.
Education & Training
- University Iowa Affiliated HospitalsFellowship, Hematology and Medical Oncology, 2002 - 2004
- St Elizabeths Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1997
- Gundersen Lutheran Medical FoundationResidency, Internal Medicine, 1993 - 1996
- Maulana Azad Medical CollegeClass of 1991
Certifications & Licensure
- CT State Medical License 2010 - 2022
- VA State Medical License 2006 - 2022
- IA State Medical License 2001 - 2018
- WI State Medical License 1995 - 2023
Publications & Presentations
PubMed
- 185 citationsDurvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinic...Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Michel M. van den Heuvel, M. Cobo, David Vicente, Alexey Smolin, Vladimi...> ;JAMA Oncology. 2020 May 1
- 12 citationsContinued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired ...Leora Horn, Scott N. Gettinger, D. Ross Camidge, Egbert F. Smit, Yelena Y. Janjigian, Vincent A. Miller, William Pao, Matthias Freiwald, Jean Fan, Bushi Wang, Vikram K...> ;Lung Cancer. 2017 Nov 1
- 269 citationsAfatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phas...Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos N. Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Salih Zeki ...> ;Lancet Oncology. 2015 Aug 1
- Join now to see all